The harm of prophylactic octreotide in pancreatoduodenectomy: more artefact than fact?  by Yang, Xihua et al.
LETTER TO THE EDITOR
The harm of prophylactic octreotide in pancreatoduodenectomy:
more artefact than fact?
We were surprised that McMillan et al.1 concluded that
octreotide may increase the risk for postoperative pancreatic
fistula (POPF). This supposition is counter to findings in multi-
ple prospective randomized controlled trials (RCTs) and meta-
analyses, which find octreotide to reduce POPF. Other RCTs,
however, have failed to show benefit. Given that, as the authors1
point out, none of the RCTs controlled well for risk of fistula,
their study controlling for fistula risk factors is laudable and long
overdue. We congratulate the authors on making another impor-
tant addition to the literature.
However, we must highlight several points regarding physiol-
ogy, published evidence and study design. Does it make physi-
ologic sense that decreasing pancreatic exocrine secretion should
increase risk for POPF? Positing an anastomosis-threatening
decrease in splanchnic blood flow, the authors cite the effect of
SMS 201-995 on flow.2 However, is a decrease of 20–25% clini-
cally relevant, given the rich blood supply of the pancreas and
jejunum? Elsewhere, research has found flow in the pancreatic
and superior mesenteric arteries to be relatively preserved com-
pared with hepatic flow,3 and that decreases in flow are mitigated
post-prandially.4 Additionally, the authors1 cite purportedly
harmful octreotide-related increases in pancreatic enzyme con-
centration, associated with a beneficial decrease in volume, as
possibly also impeding anastomotic healing, but their support-
ing evidence derives from a study with a sample size of one5 and,
like the argument for decreased splanchnic flow, this claim is
difficult to understand: given that the amylase concentration of
pancreatic fluid is 105–106 U/l, is the tiny (1.5-fold) increase
in protein output relevant? From a physiological perspective,
it seems premature to conclude that octreotide prevents
anastomotic healing.
Apropos of the published Level I evidence, including a
Cochrane review which found the incidence of POPF to be 34%
lower in the somatostatin analogue group,6 it is difficult to recon-
cile the conclusions drawn by McMillan et al.1 with the fact that
few to none of the many RCTs found significantly increased rates
of POPF in association with octreotide. Although some fault can
be found in most studies, we are nevertheless faced with multiple
prospective RCTs (most with some risk for bias), all of which show
either a significant decrease in POPF with octreotide or no
improvement, which stand in opposition to McMillan et al.’s1
single, retrospective and non-randomized, albeit beautifully
fistula-risk-score-controlled, study, also of course at some risk for
bias.
Bias, as McMillan et al.1 point out, may exist in their study
insofar that octreotide usage was not normally distributed among
surgeons, suggesting at least the possibility of an important con-
founding bias. Similarly, drains and stents were used at the
surgeon’s discretion, introducing even more heterogeneity.
We agree that the observed increase in POPF ‘is almost certainly
multifactorial’,1 but respectfully suggest, in light of the above con-
siderations, that a factor that must also be more seriously consid-
ered is ‘artefactor’.
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